Stephens Investment Management Group LLC increased its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 0.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 593,971 shares of the medical equipment provider’s stock after acquiring an additional 2,756 shares during the quarter. Stephens Investment Management Group LLC owned 0.21% of Hologic worth $26,954,000 as of its most recent SEC filing.
Other hedge funds have also recently added to or reduced their stakes in the company. Commonwealth Bank of Australia raised its holdings in shares of Hologic by 31.0% during the second quarter. Commonwealth Bank of Australia now owns 2,533 shares of the medical equipment provider’s stock valued at $114,000 after acquiring an additional 600 shares during the period. TrimTabs Asset Management LLC raised its holdings in shares of Hologic by 88.8% during the first quarter. TrimTabs Asset Management LLC now owns 2,993 shares of the medical equipment provider’s stock valued at $127,000 after acquiring an additional 1,408 shares during the period. Miles Capital Inc. acquired a new stake in shares of Hologic during the first quarter valued at approximately $206,000. Beck Mack & Oliver LLC acquired a new stake in shares of Hologic during the second quarter valued at approximately $209,000. Finally, Stratos Wealth Partners LTD. acquired a new stake in shares of Hologic during the first quarter valued at approximately $210,000. Institutional investors and hedge funds own 96.39% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Hologic, Inc. (HOLX) Stake Raised by Stephens Investment Management Group LLC” was first published by Stock Observer and is owned by of Stock Observer. If you are accessing this news story on another site, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this news story can be viewed at https://www.thestockobserver.com/2017/09/12/hologic-inc-holx-stake-raised-by-stephens-investment-management-group-llc.html.
Hologic, Inc. (NASDAQ HOLX) traded down 0.59% during trading on Tuesday, reaching $38.97. 449,757 shares of the company traded hands. The company’s 50-day moving average is $39.73 and its 200 day moving average is $42.71. The company has a market cap of $10.93 billion, a PE ratio of 14.51 and a beta of 0.92. Hologic, Inc. has a 12 month low of $35.15 and a 12 month high of $46.80.
Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.49 by $0.01. The company had revenue of $806.10 million during the quarter, compared to analysts’ expectations of $799.70 million. Hologic had a net margin of 25.65% and a return on equity of 23.18%. Hologic’s quarterly revenue was up 12.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.51 earnings per share. On average, analysts anticipate that Hologic, Inc. will post $2.01 earnings per share for the current year.
HOLX has been the topic of a number of recent analyst reports. Zacks Investment Research lowered shares of Hologic from a “hold” rating to a “sell” rating in a report on Wednesday, July 12th. Royal Bank Of Canada lowered their price objective on shares of Hologic from $50.00 to $45.00 and set a “sector perform” rating on the stock in a research report on Thursday, August 3rd. Deutsche Bank AG lowered their price objective on shares of Hologic from $51.00 to $49.00 and set a “buy” rating on the stock in a research report on Thursday, August 3rd. Barclays PLC lowered their price objective on shares of Hologic from $53.00 to $51.00 and set an “overweight” rating on the stock in a research report on Thursday, August 3rd. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and set a $51.00 price objective on shares of Hologic in a research report on Friday, July 14th. One analyst has rated the stock with a sell rating, five have given a hold rating and nine have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $48.64.
In related news, Director Lawrence M. Levy sold 7,139 shares of the business’s stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $39.04, for a total value of $278,706.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Elaine Ullian sold 8,849 shares of the business’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $45.28, for a total value of $400,682.72. Following the completion of the transaction, the director now directly owns 23,810 shares of the company’s stock, valued at approximately $1,078,116.80. The disclosure for this sale can be found here. In the last three months, insiders sold 27,594 shares of company stock valued at $1,168,871. 0.79% of the stock is currently owned by company insiders.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.